Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
ARTL halted · Volatility pause (LULD)
Artelo Biosciences files patent application for ART27.13 obesity treatment
Artelo Biosciences reports ART27.13 achieved weight loss comparable to semaglutide